wave life sciences

$172M in IPOs from Wave Life Sciences, Voyager Therapeutics

The biotech IPO parade marches on with two IPOs: Wave Life Sciences priced out at $102 million today, and Voyager Life Sciences raised $70 million.

By Meghana Keshavan

Daily

RNA therapeutics has a new player: Japan/U.S. collab WaVe Therapeutics raises $18M Series A

There’s a new player in the RNA therapeutics space: WaVe Life Sciences, a Boston-Japan biotech collaboration that just closed out an $18 million Series A. It’s working on a pipeline of stereopure nucleic acid therapeutics, which includes antisense and exon-skipping drug candidates. It says it’s working to build the “first and only” platform that can produce […]

By Meghana Keshavan

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab

A Personalized Approach to Medication Nonadherence

At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.